Risk of Changes to or Termination of Partnerships with GSK Group
First written in FY2016. 1 of 2 entries say "Materialised", first in FY2018-Q2. Latest entry: FY2018-Q2.
JCR Pharmaceuticals moved to the "Worse" side of this theme in 2017, 8 years before the typical company in this theme (2025).
The whole theme swung hardest in 2025: 3 of 9 companies on the "Worse" side.
4 other companies' latest entry also says "Materialised".
- FY2018-Q2MaterialisedAnnual report
「On 21 September 2017, the Company entered into a business and capital alliance agreement with MEDIPAL HOLDINGS CORPORATION and, on the same date, amended its comprehensive agreement with the GlaxoSmithKline Group relating to the biopharmaceutical business.」
The previously disclosed risk of a change to the agreement materialized through a change to the comprehensive agreement with the GSK Group. The text does not state that this caused delays or interruptions to product development. - FY2016First statedAnnual report
「Under this agreement, the Company intends to maintain its strategic alliance with the GSK Group and work to enhance corporate value. However, if the agreement with the GSK Group is changed or terminated due to the development status of competitors, the healthcare system or other economic conditions, resulting in delays or interruptions to the Company's product development, the Company's financial results may be materially affected.」
Discloses the possibility that the alliance with GSK plc, which holds 24.63%, may lead to delays or interruptions in product development if the agreement is changed or terminated.